Expression of Galectin-3, Cytokeratin 19, Neural Cell Adhesion Molecule and E-cadherin in Certain Variants of Papillary Thyroid Carcinoma

Czech version

Authors: J. Laco ¹; A. Ryška ¹; J. Čáp ²; P. Čelakovský ³
Authors‘ workplace: The Fingerland Department of Pathology, 2Second Department of Internal Medicine, and 3Department of Otorhinolaryngology, Charles University Faculty of Medicine and Faculty Hospital in Hradec Králové ¹
Published in: Čes.-slov. Patol., 44, 2008, No. 4, p. 103-107
Category: Original Article

Overview

The immunohistochemical expression of galectin-3 (Gal3), cytokeratin 19 (CK19), neural cell adhesion molecule (NCAM), and E-cadherin (Ecad) was evaluated to assess their use in diagnostics of papillary thyroid carcinoma (PTC). A total of 84 PTCs - 36 classical variants (cPTCs), 26 follicular variants (fPTCs), and 22 papillary microcarcinomas (mPTCs) were studied. Expression of Gal3 was found in 36/36 (100%) cPTCs, 24/26 (92%) fPTCs, and 19/22 (86%) mPTCs. CK19 expression was detected in 34/36 (94%) cPTCs, 17/26 (65%) fPTCs, and 13/22 (59%) mPTCs. Expression of NCAM was seen in 5/36 (14%) cPTCs, 7/26 (27%) fPTCs, and 9/22 (41%) mPTCs. Ecad expression was found in 23/36 (64%) cPTCs, 17/26 (65%) fPTCs, and 18/22 (82%) mPTCs. A significant difference in CK19 expression was observed between cPTC and both fPTC and mPTC (p < 0.001). Furthermore, extrathyroid tumor spread significantly correlated with both level of CK19 expression and loss of Ecad expression (p = 0.001, p = 0.04). Our findings suggest that Gal3 and CK19 are useful markers for PTC, although decreased CK19 expression in mPTC and fPTC must be considered. Furthermore, CK19 and Ecad may play a role in extrathyroid tumor spread.

Key words:
papillary thyroid carcinoma – galectin-3 – cytokeratin 19 – neural cell adhesion molecule – E-cadherin

Sources

1. Baloch, Z.W., Abraham, S., Roberts, S. et al.: Differential expression of cytokeratins in follicular variant of papillary carcinoma: an immunohistochemical study and its diagnostic utility. Hum. Pathol., 30, 1999, s. 1166-1171.

2. Bartolazzi, A., Gasbarri, A., Papotti, M. et al.: Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet, 357, 2001, s. 1644-1650.

3. Beesley, M.F., McLaren, K.M.: Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules. Histopathology, 41, 2002, s. 236-243.

4. Brabant, G., Hoang-Vu, C., Cetin, Y. et al.: E-cadherin: a differentiation marker in thyroid malignancies. Cancer Res., 53, 1993, s. 4987-4993.

5. Casey, M.B., Lohse, C.M., Lloyd, R.V.: Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1. Endocr. Pathol., 14, 2003, s. 55-60.

6. Castronovo, V., Van Den Brule, F.A., Jackers, P. et al.: Decreased expression of galectin-3 is associated with progression of human breast cancer. J. Pathol., 179, 1996, s. 43-48.

7. Coli, A., Bigotti, G., Zucchetti, F. et al.: Galectin-3, a marker of well-differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia. Histopathology, 40, 2002, s. 80-87.

8. Crossin, K.L., Krushel, L.A.: Cellular signaling by neural cell adhesion molecules of the immunoglobulin superfamily. Dev. Dyn., 218, 2000, s. 260-279.

9. DeLellis, R.A., Lloyd, R.V., Heitz, P.H., Eng, Ch.: WHO Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. Lyon: IARCPress, 2004, s. 57-66.

10. de Matos, P.S., Ferreira, A.P., de Oliveira Facuri, F. et al.: Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology, 47, 2005, s. 391-401.

11. Herrmann, M.E., LiVolsi, V.A., Pasha, T.L. et al.: Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. Arch. Pathol. Lab. Med., 126, 2002, s. 710-713.

12. Huang, S.H., Wu, J.C., Chang, K.J. et al.: Expression of the cadherin-catenin complex in well-differentiated human thyroid neoplastic tissue. Thyroid, 9, 1999, s. 1095-1103.

13. Cheung, C.C., Ezzat, S., Freeman, J.L. et al.: Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod. Pathol., 14, 2001, s. 338-342.

14. Kawachi, K., Matsushita, Y., Yonezawa, S. et al.: Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. Hum. Pathol., 31, 2000, s. 428-433.

15. Laco, J., Ryška, A.: The use of immunohistochemistry in the differential diagnosis of thyroid gland tumors with follicular growth pattern. Čes.-slov. Patol., 42, 2006, s. 120-124 (in Czech).

16. Lam, K.Y., Lui, M.C., Lo, C.Y.: Cytokeratin expression profiles in thyroid carcinomas. Eur. J. Surg. Oncol., 27, 2001, s. 631-635.

17. Liu, F.T., Patterson, R.J., Wang, J.L.: Intracellular functions of galectins. Biochim. Biophys. Acta, 1572, 2002, s. 263-273.

18. Martins, L., Matsuo, S.E., Ebina, K.N. et al.: Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors. J. Clin. Endocrinol. Metab., 87, 2002, s. 4806-4810.

19. Mehrotra, P., Okpokam, A., Bouhaidar, R. et al.: Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms. Histopathology, 45, 2004, s. 493-500.

20. Miettinen, M., Kovatich, A.J., Karkkainen, P.: Keratin subsets in papillary and follicular thyroid lesions. A paraffin section analysis with diagnostic implications. Virchows Arch., 431, 1997, s. 407-413.

21. Moll, R., Franke, W.W., Schiller, D.L. et al.: The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell, 31, 1982, s. 11-24.

22. Naito, A., Iwase, H., Kuzushima, T. et al.: Clinical significance of E-cadherin expression in thyroid neoplasms. J. Surg. Oncol., 76, 2001, s. 176-180.

23. Oestreicher-Kedem, Y., Halpern, M., Roizman, P. et al.: Diagnostic value of galectin-3 as a marker for malignancy in follicular patterned thyroid lesions. Head Neck, 26, 2004, s. 960-966.

24. Prasad, M.L., Pellegata, N.S., Huang, Y. et al.: Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod. Pathol., 18, 2005, s. 48-57.

25. Raphael, S.J., McKeown-Eyssen, G., Asa, S.L.: High-molecular-weight cytokeratin and cytokeratin-19 in the diagnosis of thyroid tumors. Mod. Pathol., 7, 1994, s. 295-300.

26. Rosai, J., Kuhn, E., Carcangiu, M.L.: Pitfalls in thyroid tumour pathology. Histopathology, 49, 2006, s. 107-120.

27. Scarpino, S., Di Napoli, A., Melotti, F. et al.: Papillary carcinoma of the thyroid: low expression of NCAM (CD56) is associated with downregulation of VEGF-D production by tumour cells. J. Pathol., 212, 2007, s. 411-419.

28. Scheumman, G.F., Hoang-Vu, C., Cetin, Y. et al.: Clinical significance of E-cadherin as a prognostic marker in thyroid carcinomas. J. Clin. Endocrinol. Metab., 80, 1995, s. 2168-2172.

29. Schoeppner, H.L., Raz, A., Ho, S.B. et al.: Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon. Cancer, 75, 1995, s. 2818-2826.

30. Sobrinho-Simoes, M., Preto, A., Rocha, A.S. et al.: Molecular pathology of well-differentiated thyroid carcinomas. Virchows Arch., 447, 2005, s. 787-793.

31. Van Aken, E., De Wever, O., Correia da Rocha, A.S. et al.: Defective E-cadherin/catenin complexes in human cancer. Virchows Arch., 439, 2001, s. 725-751.

32. van den Brule, F.A., Waltregny, D., Liu, F.T. et al.: Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression. Int. J. Cancer, 89, 2000, s. 361-367.

33. Vargas, F., Tolosa, E., Sospedra, M. et al.: Characterization of neural cell adhesion molecule (NCAM) expression in thyroid follicular cells: induction by cytokines and over-expression in autoimmune glands. Clin. Exp. Immunol., 98, 1994, s. 478-488.

34. Volante, M., Bozzalla-Cassione, F., Orlandi, F. et al.: Diagnostic role of galectin-3 in follicular thyroid tumors. Virchows Arch., 444, 2004, s. 309-312.

35. Zeromski, J., Biczysko, M., Stajgis, P. et al.: CD56(NCAM) antigen in glandular epithelium of human thyroid: light microscopic and ultrastructural study. Folia Histochem. Cytobiol., 37, 1999, s. 11-17.

Labels

Anatomical pathology Forensic medical examiner Toxicology

What is New in Pathology of the Thyroid Gland?

Rafting in the Membrane. A Lesson Learnt from Lymphoproliferative Disorders

Cutaneous Squamous Cell Carcinoma of Different Grades: Variation of the Expression of CD10

Article was published in

Czecho-Slovak Pathology

2008 Issue 4